Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy PharmaphorumPharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.Read full story pharminent June 24, 2026 (Last updated: June 24, 2026) Pharmaphorum Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CARsgen’s Satri-cel Wins World-First CAR-T Approval for Solid TumorNext: Boehringer and Combotope partner for cancer antibodies Related Stories Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026 Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026
